| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MCSFR |
| Uniprot No | P07333 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-512aa |
| 氨基酸序列 | IPVIEPSVPELVVKPGATVTLRCVGNGSVEWDGPPSPHWTLYSDGSSSIL STNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPWNVLAQEVVVFE DQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTIHRAKF IQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEA AQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVD FQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGL NLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLP RLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIWTFINGSGTLLC AASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLSQEPFHKVTVQ SLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPPDE |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MCSFR(CSF1R)重组蛋白的构造参考文献示例，供参考：
---
1. **标题**: *Structural and Functional Analysis of Recombinant Human M-CSFR Expressed in Insect Cells*
**作者**: Smith, J., et al.
**摘要**: 该研究利用杆状病毒-昆虫细胞系统表达重组人M-CSFR胞外域，通过X射线晶体学解析其三维结构，并验证其与配体M-CSF的结合活性，为靶向受体药物设计提供结构基础。
2. **标题**: *Recombinant M-CSFR in Cancer Immunotherapy: Targeting Tumor-Associated Macrophages*
**作者**: Lee, H., & Park, S.
**摘要**: 开发哺乳动物细胞来源的重组M-CSFR蛋白，用于筛选抑制性抗体，阻断肿瘤微环境中巨噬细胞的招募，在动物模型中显著抑制肿瘤生长。
3. **标题**: *Optimization of Soluble M-CSFR Production in E. coli for High-Throughput Screening*
**作者**: Zhang, Y., et al.
**摘要**: 报道在大肠杆菌中优化重组M-CSFR胞外段的可溶性表达与纯化工艺，验证其用于高通量筛选激酶抑制剂的效果，降低成本并提升效率。
4. **标题**: *Role of Recombinant M-CSFR in Autoimmune Disease Models*
**作者**: Müller, R., et al.
**摘要**: 利用重组M-CSFR蛋白探究其在类风湿性关节炎模型中的作用，证实其调控巨噬细胞活化，为自身免疫疾病治疗提供新靶点。
---
**说明**：以上文献为示例，实际引用需通过学术数据库(如PubMed、Google Scholar)检索真实文献。建议使用关键词“CSF1R recombinant protein”“M-CSFR expression”或结合研究领域(如“cancer”“structural biology”)进一步筛选。
Macrophage colony-stimulating factor receptor (M-CSFR), also known as CSF1R or CD115. is a tyrosine kinase receptor critical for the development, survival, and function of mononuclear phagocytes, including macrophages, monocytes, and osteoclasts. It binds to its ligands, M-CSF (CSF1) and IL-34. activating downstream signaling pathways such as PI3K/AKT, MAPK, and JAK/STAT. These pathways regulate cellular proliferation, differentiation, and immune responses. Dysregulation of M-CSFR is implicated in diseases like cancer, inflammatory disorders, and bone remodeling defects.
Recombinant M-CSFR proteins are engineered versions produced via heterologous expression systems (e.g., mammalian, insect, or bacterial cells) for research and therapeutic applications. They typically include extracellular ligand-binding domains or full-length receptors modified with tags (e.g., Fc or His tags) to facilitate purification and detection. These proteins are essential tools for studying receptor-ligand interactions, signal transduction mechanisms, and drug screening. For example, recombinant soluble M-CSFR is used to block ligand-receptor binding in autoimmune or cancer models, helping to validate therapeutic targets.
In therapeutics, M-CSFR inhibition has gained attention for targeting tumor-associated macrophages (TAMs) that promote tumor progression and immune evasion. Drugs like pexidartinib (a CSF1R inhibitor) leverage this mechanism, showing efficacy in clinical trials for tenosynovial giant cell tumors. Recombinant M-CSFR variants also aid in developing bispecific antibodies or chimeric antigen receptor (CAR) therapies. However, challenges remain in optimizing receptor stability, minimizing off-target effects, and understanding context-dependent signaling. Ongoing research focuses on refining recombinant designs and exploring combination therapies to enhance clinical outcomes.
×
